[go: up one dir, main page]

AR096236A1 - Anticuerpos de dominio simple vhh dirigidos a norovirus gi.1 y gii.4 y sus usos - Google Patents

Anticuerpos de dominio simple vhh dirigidos a norovirus gi.1 y gii.4 y sus usos

Info

Publication number
AR096236A1
AR096236A1 ARP140101882A ARP140101882A AR096236A1 AR 096236 A1 AR096236 A1 AR 096236A1 AR P140101882 A ARP140101882 A AR P140101882A AR P140101882 A ARP140101882 A AR P140101882A AR 096236 A1 AR096236 A1 AR 096236A1
Authority
AR
Argentina
Prior art keywords
norovirus
disclosed
antibodies
vhh
nucleic acids
Prior art date
Application number
ARP140101882A
Other languages
English (en)
Inventor
Parreo Viviana
Pamela Aguilar Andrea
Bok Marina
Laura Garaicoechea Lorena
Bok Karin
Kim Green Lisbeth
Vladimirovich Sosnovtsev Stanislav
Original Assignee
The Us Secretary Dept Of Health And Human Services Nat Inst Of Health Office Of Tech Transfer
Inst Nac De Tecnología Agropecuaria (Inta)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Us Secretary Dept Of Health And Human Services Nat Inst Of Health Office Of Tech Transfer, Inst Nac De Tecnología Agropecuaria (Inta) filed Critical The Us Secretary Dept Of Health And Human Services Nat Inst Of Health Office Of Tech Transfer
Publication of AR096236A1 publication Critical patent/AR096236A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se divulgan anticuerpos monoclonales aislados VHH que se unen en forma específica al polipéptido del Norovirus. En algunas formas de realización, el Norovirus es un Norovirus del Grupo génico I o un Norovirus del Grupo génico II. En otras formas de realización, el Norovirus es Norwalk o virus MD2004. En algunas formas de realización, los anticuerpos monoclonales se unen en forma específica a VP1. Además, se divulgan composiciones entre los que se incluye los anticuerpos divulgados, ácidos nucleicos que codifica estos anticuerpos, vectores de expresión entre los que se incluye los ácidos nucleicos, y células huésped aisladas que expresan los ácidos nucleicos. Los anticuerpos y composiciones divulgados en este documento pueden utilizarse para la detección de la presencia de un Norovirus en una muestra biológica, o detectar una infección producida por el Norovirus. Además se divulgan métodos de tratamiento y/o prevención de una infección producida por NoV.
ARP140101882A 2013-05-09 2014-05-09 Anticuerpos de dominio simple vhh dirigidos a norovirus gi.1 y gii.4 y sus usos AR096236A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361821354P 2013-05-09 2013-05-09

Publications (1)

Publication Number Publication Date
AR096236A1 true AR096236A1 (es) 2015-12-16

Family

ID=50877692

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101882A AR096236A1 (es) 2013-05-09 2014-05-09 Anticuerpos de dominio simple vhh dirigidos a norovirus gi.1 y gii.4 y sus usos

Country Status (4)

Country Link
US (3) US10000556B2 (es)
EP (2) EP3583950A1 (es)
AR (1) AR096236A1 (es)
WO (1) WO2014183052A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3583950A1 (en) * 2013-05-09 2019-12-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use
EP3604540A4 (en) * 2017-03-31 2020-12-23 The University of Tokyo NOROVIRUS ANTIBODIES
KR101966525B1 (ko) * 2017-06-19 2019-04-08 전남대학교산학협력단 감염형 노로바이러스의 선별 방법
JP2019011297A (ja) 2017-06-30 2019-01-24 パナソニックＩｐマネジメント株式会社 ノロウイルスに結合する抗体、複合体、それを用いた検出装置及び検出方法
BR112020010799A2 (pt) * 2017-11-30 2020-11-10 Medicago Inc. proteínas vp1 modificadas de norovírus e vlps que compreendem proteínas vp1 modificadas de norovírus
WO2019179365A1 (en) * 2018-03-20 2019-09-26 WuXi Biologics Ireland Limited Novel anti-lag-3 antibody polypeptide
JPWO2020036135A1 (ja) * 2018-08-13 2021-08-10 一般財団法人阪大微生物病研究会 ヒトノロウイルス様粒子およびその使用
JP7190674B2 (ja) * 2018-08-23 2022-12-16 パナソニックＩｐマネジメント株式会社 ノロウイルスに結合する抗体、複合体、それを用いた検出装置及び検出方法
JP7190675B2 (ja) 2018-08-23 2022-12-16 パナソニックＩｐマネジメント株式会社 ノロウイルスに結合する抗体、複合体、それを用いた検出装置及び検出方法
AU2021256984A1 (en) * 2020-04-14 2022-12-01 Scaled Microbiomics, Llc Treating or preventing travelers diarrhea
US20230258637A1 (en) * 2020-10-12 2023-08-17 Universite De Lille Methods for detecting a target in a sample using mutated nanobodies
EP4317436A4 (en) * 2021-03-29 2025-04-23 Denka Company Limited Peptide of norovirus origin, polynucleotide, antibody, composition, method for identifying neutralizing epitope for norovirus
CN114736292B (zh) * 2022-06-10 2023-03-07 广州明药科技有限公司 靶向诺如病毒蛋白的纳米抗体及其应用
CN120584130A (zh) * 2022-11-29 2025-09-02 佛罗里达大学研究基金会公司 用纳米抗体靶向gpr158(mglyr)用于治疗益处
WO2024182862A1 (en) * 2023-03-09 2024-09-12 Griffith University Nanobody for norovirus
WO2024233099A1 (en) * 2023-05-05 2024-11-14 Regeneron Pharmaceuticals, Inc. Labeling and anti-drug antibody assays for aav vectors
CN119061208B (zh) * 2024-11-06 2025-03-11 北京市疾病预防控制中心 诺如病毒全基因组测序的引物组、试剂盒及方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
JP2955759B2 (ja) 1988-07-20 1999-10-04 セゲブ・ダイアグノスティックス・インコーポレイテッド 核酸配列を増幅及び検出する方法
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IT1231156B (it) 1989-07-19 1991-11-19 Eniricerche Spa Espressione e secrezione di interleuchina 1 beta umana matura in bacillus subtilis e mezzi e metodi per il suo ottenimento.
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5427930A (en) 1990-01-26 1995-06-27 Abbott Laboratories Amplification of target nucleic acids using gap filling ligase chain reaction
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
DE69311538D1 (de) 1992-03-12 1997-07-17 Alkermes Inc Acth enthaltende mikrokugeln mit gesteuerter abgabe
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
EP0671926B1 (en) 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
EP1589107B1 (en) 1992-08-21 2009-12-23 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
CA2195209C (en) 1994-07-15 2008-09-23 Roy R. Sooknanan Use of rna polymerase to improve nucleic acid amplification process
AT402203B (de) 1995-06-13 1997-03-25 Himmler Gottfried Dipl Ing Dr Verfahren zur transkriptionsfreien amplifizierung von nucleinsäuren
JP3185206B2 (ja) 1995-07-20 2001-07-09 田辺製薬株式会社 消化管下部放出型被覆カプセル製剤
US6100388A (en) 1998-03-16 2000-08-08 Biogaia Biologies Ab Lactobacilli harboring aggregation gene as a vaccine delivery vehicle
US7138143B1 (en) 1999-09-30 2006-11-21 Otsuka Pharmaceutical Company, Limited Coated preparation soluble in the lower digestive tract
US7304208B2 (en) 2000-05-02 2007-12-04 Ventria Bioscience Expression of human serum albumin (HSA) in monocot seeds
US7417178B2 (en) 2000-05-02 2008-08-26 Ventria Bioscience Expression of human milk proteins in transgenic plants
CA2441903C (en) 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
US7282205B2 (en) 2001-11-07 2007-10-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-hepatitis A virus antibodies
US8105592B2 (en) 2004-11-25 2012-01-31 Vhsquared Limited Heavy chain and single domain antibodies
NZ596322A (en) 2006-01-17 2013-02-22 Synthon Biopharmaceuticals Bv Compositions and methods for humanization and optimization of N-glycans in duckweed plants
EP2049152A2 (en) * 2006-06-30 2009-04-22 Kim Laboratories, Inc. Antibodies for norovirus
CA2675115C (en) 2007-01-12 2014-12-09 Actogenix N.V. Lactococcus promoters and uses thereof
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
CA2774636C (en) 2009-09-25 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use
GB201115214D0 (en) 2011-09-02 2011-10-19 Health Prot Agency Influenza virus antibody compositions
KR102000479B1 (ko) * 2011-09-13 2019-07-16 덴카 세이켄 가부시키가이샤 항인간 노로바이러스 gii 항체
EP3583950A1 (en) * 2013-05-09 2019-12-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use

Also Published As

Publication number Publication date
US20180251527A1 (en) 2018-09-06
US20200283507A1 (en) 2020-09-10
US20160102136A1 (en) 2016-04-14
EP3583950A1 (en) 2019-12-25
US10662238B2 (en) 2020-05-26
EP2994163B1 (en) 2019-08-28
US11325965B2 (en) 2022-05-10
EP2994163A1 (en) 2016-03-16
US10000556B2 (en) 2018-06-19
WO2014183052A1 (en) 2014-11-13

Similar Documents

Publication Publication Date Title
AR096236A1 (es) Anticuerpos de dominio simple vhh dirigidos a norovirus gi.1 y gii.4 y sus usos
AR131695A2 (es) Anticuerpo que se une a miostatina latente y ácido nucleico que lo codifica
CY1122223T1 (el) Προσμειξεις dna σε συνθεση που περιεχει ενα παρβοϊικο ιοσωματιο
CY1125443T1 (el) Μη φουκοζυλιωμενα anti-fgfr2iiib αντισωματα
AR134186A2 (es) Un anticuerpo anti-csf-1r, un proceso para producirlo, una composición farmacéutica que lo comprende, una secuencia de adn aislado, un vector de expresión o clonación y una célula hospedadora
CL2018003510A1 (es) Anticuerpos antagonistas que se unen en forma de t a tgfb1, tgfb2 y tgfb3 humano, y su uso en el tratamiento de fibrosis pulmonar.
ECSP19033211A (es) ANTICUERPOS ANTI–C1s Y MÉTODOS DE USO DE LOS MISMOS
EA201892616A1 (ru) Антитела к pd1 и lag3 для лечения злокачественного новообразования
CY1121934T1 (el) Αντισωματα anti-fcrn
CO2017006651A2 (es) Anticuerpos anti-c5
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
CO2017005842A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
CL2018000106A1 (es) Moléculas de anticuerpo que se unen a cd45
EA201990017A1 (ru) Антитела к миостатину и способы их применения
MX2015016798A (es) Regulacion transcripcional guiada por acido ribonucleico.
MX2015009594A (es) Construcciones de anticuerpos para cdh19 y cd3.
CL2016000959A1 (es) Adenovirus oncolíticos armados con genes heterologos
EA201792080A1 (ru) Гуманизированные анти-c1s антитела и способы их применения
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
MX2016010360A (es) Moleculas de anticuerpo para el virus del dengue y uso de las mismas.
EA201891420A1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
BR112017003582A2 (pt) anticorpos, composições e usos
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
EA201600252A1 (ru) Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования

Legal Events

Date Code Title Description
FG Grant, registration